Previous 10 | Next 10 |
The following slide deck was published by AVROBIO, Inc. in conjunction with this Read more ...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Patient identification for clinical trials continues; dosing temporarily paused as clinical trial sites focus on COVID-19 pandemic Essential laboratory and manufacturing activities currently uninterrupted Cash runway into Q2 2022 AVROBIO, Inc. (Nasdaq:AVRO), a leading clin...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team will participate at three upcoming virtual investor conferences: Guggenheim Healthcar...
The following slide deck was published by AVROBIO, Inc. in conjunction with this Read more ...
AVROBIO (NASDAQ: AVRO ): Q4 GAAP EPS of -$0.72 misses by $0.11 . More news on: AVROBIO, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Presented positive data at the 16 th Annual WORLD Symposium ™ on AVR-RD-04 for cystinosis and AVR-RD-01 for Fabry disease, as well as early data on plato™-produced drug product and plasma enzyme activity level Received orphan drug designation from U.S. Food and Drug Adm...
AVR-RD-04 is the third AVROBIO investigational gene therapy to receive orphan status AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the U.S. Food and Drug Administratio...
AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Geoff MacKay, president and CEO of AVROBIO, will present at the Cowen and Company 40 th Annual Health Care Conference at 4:50 p.m. E...
News, Short Squeeze, Breakout and More Instantly...
2024-06-20 09:02:05 ET AvroBio Inc (AVRO) announced stock split at a ratio of 1-for-12 on 2024-06-21 ... Full story available on KlickAnalytics.com
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Swire Pacific Ltd. ADR (Class A) (SWRAY) is expected to report for Q4 2023 Troika Media Group Inc. (TRKAQ) is expected to report for quarter end 2023-12-31 American Environmental Partners Inc. (AEPT) is expected to report for quarter end 2023-12-31 Veolia Environnement S.A. ADR (VEOEY...